Un estudio optimiza las probabilidades de éxito de la terapia celular alogénica en pacientes con insuficiencia cardiaca
Researchers from the Heart Disease Research Group at the IGTP and the CIBER Cardiovascular Group both led by Dr Antoni Bayés prepare the way to optimize reparative cell therapy in heart failure patients. The study, carried out in conjunction with the Immunogenetics and Histocompatibility Laboratory and the Cell Therapy Unit of the Blood and Tissue Bank of Barcelona has studied the HLA allele and the frequency of haplotypes in a cohort of patients with heart failure as the first stage in optimizing future allogenic cell therapies for these patients.
![](/media/upload/gif/20190201-sroura_154902709758.jpg)